PCVX Share Price | Vaxcyte, Inc. Stock Analysis & Recommendation

Q: How big is Vaxcyte, Inc.?

Market Cap: As of Jun 18, Vaxcyte, Inc. has a market capitalization of 4,339.70 million, categorizing it as a Mid Cap company.Recent Quarterly Performance: For the latest four quarters, Vaxcyte, Inc. reported net sales of 0.00 million and a net profit of -509.62 million.Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds amounting to 3,305.82 million and total assets of 3,533.30 million.

Q: What does Vaxcyte, Inc. do?

Overview:Vaxcyte, Inc. is a vaccine company focused on developing vaccines to prevent or treat common and deadly infectious diseases worldwide, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.Financial Snapshot:- Most recent Net Profit: -141 Million (Quarterly Results - Mar 2025)- Market-cap: USD 4,339.70 Million (Mid Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -0.52- Return on Equity: -15.93%- Price to Book: 1.36Contact Details:- Address: 353 Hatch Dr, Foster City, CA 94404- Tel: 1 650 8370111- Website: https://vaxcyte.com/

Q: Is Vaxcyte, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for Vaxcyte, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The daily moving averages are bearish, while the weekly Bollinger Bands and KST are both mildly bearish. The overall stance is mildly bearish, reflecting a lack of strong upward momentum.In terms of performance, Vaxcyte has underperformed the S&P 500 significantly over the past year, with a return of -72.04% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

438.31 k

Shareholding (Dec 2025)

FII

15.56%

Held by 181 FIIs

DII

22.09%

Held by 78 DIIs

Promoter

2.82%

How big is Vaxcyte, Inc.?

22-Jun-2025

As of Jun 18, Vaxcyte, Inc. has a market capitalization of $4.34 billion, with net sales of $0.00 million and a net profit of -$509.62 million over the latest four quarters. As of Dec 24, the company has shareholder's funds of $3.31 billion and total assets of $3.53 billion.

View full answer

What does Vaxcyte, Inc. do?

22-Jun-2025

Vaxcyte, Inc. is a mid-cap vaccine company focused on developing vaccines for infectious diseases. As of March 2025, it reported a net profit loss of $141 million and has a market cap of approximately $4.34 billion.

View full answer

Who are in the management team of Vaxcyte, Inc.?

22-Jun-2025

As of March 2022, the management team of Vaxcyte, Inc. includes Dr. Moncef Slaoui (Chairman), Mr. Grant Pickering (CEO, Co-Founder), and several directors: Ms. Halley Gilbert, Mr. Patrick Heron, Dr. Peter Hirth, Dr. Robert Hopfner, and Dr. Heath Lukatch. They oversee the company's strategic direction and operations.

View full answer

Is Vaxcyte, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Vaxcyte, Inc. shows a mildly bearish trend with mixed signals from technical indicators, underperforming the S&P 500 by -72.04% compared to its 17.14% return over the past year.

View full answer

Compare Vaxcyte, Inc. with Similar Stocks

Halozyme Therapeutics, Inc.Elanco Animal Health, Inc.Bio-Techne Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 8,005 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.59

Return on Equity

-22.72%

Price to Book

2.77

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-247 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

17.33%

6 Months

70.35%

1 Year

-24.26%

2 Years

-16.84%

3 Years

47.75%

4 Years

128.48%

5 Years

153.91%

Vaxcyte, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-249.39%

EBIT to Interest (avg)

-298.88

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.52

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.77

EV to EBIT

-7.76

EV to EBITDA

-7.96

EV to Capital Employed

5.31

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-68.35%

ROE (Latest)

-22.72%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 92 Schemes (59.53%)

Foreign Institutions

Held by 181 Foreign Institutions (15.56%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -79.80% vs 24.17% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-264.50",
          "val2": "-157.40",
          "chgp": "-68.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-246.50",
          "val2": "-137.10",
          "chgp": "-79.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -65.25% vs -15.31% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-898.80",
          "val2": "-553.70",
          "chgp": "-62.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-766.60",
          "val2": "-463.90",
          "chgp": "-65.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-264.50

-157.40

-68.04%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-246.50

-137.10

-79.80%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -79.80% vs 24.17% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-898.80

-553.70

-62.33%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-766.60

-463.90

-65.25%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -65.25% vs -15.31% in Dec 2024

All Annual Results

Company CV

About Vaxcyte, Inc.

Vaxcyte, Inc.

Pharmaceuticals & Biotechnology

Vaxcyte Inc. is a vaccine company. The Company is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes pneumococcal conjugate vaccine (PCV) candidates. Its lead vaccine candidate is VAX-24, a 24-valent investigational PCV. Its pipeline also includes VAX-XP, VAX-A1 and VAX-PG. The Company's second PCV, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. VAX-PG is being developed as a protein vaccine for the treatment of periodontitis.

Company Coordinates

Company Details

353 Hatch Dr , FOSTER CITY CA : 94404

Tel: 1 650 8370111

https://vaxcyte.com/

Registrar Details